289469-67-6

Basic information

• Product Name: 4-ethoxy-2-(3-nitrophenyl)pyridine
• Synonyms: 4-ethoxy-2-(3-nitrophenyl)pyridine
• CAS NO: 289469-67-6
• Molecular Weight: 244.25
• Mol File: 289469-67-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-ethoxy-2-(3-nitrophenyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ethoxy-2-(3-nitrophenyl)pyridine(289469-67-6)
• EPA Substance Registry System: 4-ethoxy-2-(3-nitrophenyl)pyridine(289469-67-6)

Safety Data

• Hazardous Substances Data: 289469-67-6(Hazardous Substances Data)

Upstream product

• 73583-37-6 2-chloro-4-bromopyridine 
• 52311-50-9 2-chloro-4-ethoxy-pyridine 
• 13331-27-6 m-nitrobenzene boronic acid 
• 14221-01-3 tetrakis(triphenylphosphine) palladium⁽⁰⁾ 
• 17117-13-4 2-bromo-4-ethoxy-pyridine 

Downstream Products

• 289469-68-7 3-(4-ethoxypyridin-2-yl)aniline 

Relevant articles and documents

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Pyridine compounds and their pharmaceutical use

A compound of formula (I) wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NOS(nitric oxide synthasey)-mediated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, insulin-ependent diabetes mellitus, ulcerative colitis, cerebral infarction, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, pain, ulcer, and the like in human being and animals.